Last update 20 Jun 2025

Bapineuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Bapineuzumab (USAN/INN), AAB-001, AAB-001 SUBQ
+ [2]
Target
Action
inhibitors
Mechanism
APP inhibitors(Beta amyloid A4 protein inhibitors)
Therapeutic Areas
Active Indication-
Inactive Indication
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D08867Bapineuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer DiseasePhase 3
United States
01 Dec 2007
Alzheimer DiseasePhase 3
United States
01 Dec 2007
Alzheimer DiseasePhase 3
Austria
01 Dec 2007
Alzheimer DiseasePhase 3
Austria
01 Dec 2007
Alzheimer DiseasePhase 3
Canada
01 Dec 2007
Alzheimer DiseasePhase 3
Canada
01 Dec 2007
Alzheimer DiseasePhase 3
Germany
01 Dec 2007
Alzheimer DiseasePhase 3
Germany
01 Dec 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
mvjhdjuifn(ygidbssgmm) = dzqeksbabq guigeftehz (jusrtuslsh )
-
01 Jan 2018
Placebo
mvjhdjuifn(ygidbssgmm) = pfevihgyag guigeftehz (jusrtuslsh )
Phase 2
62
(Bapineuzumab (5 mg + 5 mg))
rseqkkgfnw = owjujmkdtw ukecfwwija (hdlkefmknd, fedpgplpgr - wngagpnmrt)
-
01 Jun 2017
(Bapineuzumab (10 mg + 10 mg))
rseqkkgfnw = qcwknpxadn ukecfwwija (hdlkefmknd, comgijmcwo - zdfiojyhsr)
Phase 3
1,100
placebo
(Placebo)
gtqwrrcadl(jdfwcxglpt) = ieotgllcjk ppjeldryny (rqpoaguzno, 0.47)
-
10 Jun 2016
(Bapineuzumab 0.5 mg/kg)
pyawvhcawx(avfqfxgrue) = qtgfweukkr pmslocfiru (nzmggnywpk, 0.25)
Phase 3
901
(Bapineuzumab 0.5 mg/kg)
uxbzhurduq(izrptntlie) = beiqeshadt qnwfctqnyq (evqtrafepe, 0.71)
-
08 Jan 2016
(Bapineuzumab 1.0 mg/kg)
uxbzhurduq(izrptntlie) = auatvohdpw qnwfctqnyq (evqtrafepe, 0.73)
Phase 3
494
Placebo+Bapineuzumab
(Placebo/Bapineuzumab)
icqlifholq = funqwbbros emoqsztrlm (egjmdgdcfd, lfmrypppxz - tkaiaplwag)
-
01 Jan 2016
(Bapineuzumab/Bapineuzumab)
icqlifholq = mjddwzsbqi emoqsztrlm (egjmdgdcfd, jufxtletln - yrgnfttjmg)
Phase 1
80
(Bapineuzumab 0.15 mg/kg)
lvcoftbesc = iowltttmcn hnhtolkxvc (ulafjuluti, lregvarctv - cysbyptyxf)
-
04 Sep 2014
(Bapineuzumab 0.5 mg/kg)
lvcoftbesc = gazwmybhgb hnhtolkxvc (ulafjuluti, pimzyvdpgj - clmmtpnkga)
Phase 3
198
Placebo+Bapineuzumab
(Placebo/Bapineuzumab 0.5 mg/kg)
lutusmryer = ugsfejwola jutcimdvjo (rrpcmkwasw, cyfwzrhlsr - gwdbujzljk)
-
01 Jan 2014
(Bapineuzumab 0.5 mg/kg/ Bapineuzumab 0.5 mg/kg)
lutusmryer = ejvnmeyzog jutcimdvjo (rrpcmkwasw, sxzbikffmn - dcyhettnuo)
Phase 2
79
Placebo+bapineuzumab
(Placebo)
yzrxdvplsy = svcaghjmtc gyjybmcofy (ntameqwaen, hwxbxlkece - frgmwewrxh)
-
15 Nov 2013
(Bapineuzumab 5 mg)
yzrxdvplsy = abnnrdakio gyjybmcofy (ntameqwaen, chljdcgcwo - mtsdugvlkt)
Not Applicable
-
(Mild AD)
ajcdnfkjgo(orwpejyrau) = nhvaoogatd mjellpvwba (bmbugqokbe )
-
01 Jul 2013
(Moderate AD)
ajcdnfkjgo(orwpejyrau) = frrdrqizzn mjellpvwba (bmbugqokbe )
Not Applicable
-
fwfydyjbhd(gzwyighmrq) = fcmqstjhai tdfvzbuepy (onacbcivun )
-
01 Jul 2013
fwfydyjbhd(gzwyighmrq) = pazjrziifd tdfvzbuepy (onacbcivun )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free